

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. University Healthcare-Berkeley Medical Center 2. 2500 Hospital Drive Martinsburg, WV 25401		In accordance with letter dated May 26, 2022, 3. License No.: 47-15501-01 is amended in its entirety to read as follows:	4. Expiration Date: October 31, 2025 5. Docket No.: 030-09218 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200	7. Chemical and/or physical form A. Any B. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-15501-01

Docket or Reference No.:
030-09218

Amendment No. 35

- | | | | |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| C. Iodine-125 | C. Sealed Sources (Amersham Health/Medi-Physics, Inc., Model Model 6702; Bard Brachytherapy, Inc., Model Model STM 125I; BEBIG Isotopentechnik und Umweltdiagnostik, Model Model I25.S06; Best Medical International, Inc., Model Model 2301; Core Oncology, Inc. (formerly Mills Biopharmaceuticals, LLC, Model Model I-125 SL; IsoAid, LLC, Model Model IAI-125A; Medi-Physics, Inc. D/B/A GE Healthcare, Model Model 6711; Medi-Physics, Inc. or Amersham Health, Model Model 6733; North American Scientific, Inc., Model Model MED3631) | C. 2.5 curies total | C. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75. |
| D. Any byproduct material permitted by 10 CFR 35.500 | D. Sealed Sources | D. 10 millicuries per source and 40 millicuries total | D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g). |
| E. Any byproduct material permitted by 10 CFR 31.11 | E. Prepackaged Kits (Isotope Product Laboratories, Model Model PHI-0094) | E. 5 millicuries total | E. For use in in-vitro studies. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-15501-01

Docket or Reference No.:
030-09218

Amendment No. 35

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 2500 Hospital Drive, Martinsburg, West Virginia.
11. The Radiation Safety Officer (RSO) for this license is Vivek P Padha, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User (M.D., D.O., etc.)</u>	<u>Material and Use</u>
John L. Blanco, M.D.	10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.500
Edward Kiggundu, M.D.	10 CFR 35.400
Vivek P. Padha, M.D.	10 CFR 35.100, 10 CFR 35.200
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 47-15501-01

Amendment No. 35

Docket or Reference No.:
030-09218

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated July 20, 2015 [ML15230A407]
 - B. Letter dated September 2, 2015 [ML15273A395]
 - C. Letter dated January 25, 2022 [ML22047A114] (Delegation of Authority Only)
 - D. Letter dated March 22, 2022 [ML22081A293]
 - E. Letter dated May 26, 2022 [ML22214B602] (Delegation of Authority only)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 18, 2022By: _____
Robert Gallagher
Region 1